Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Impact of filgotinib on sacroiliac joint magnetic resonance imaging structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial)

Research output: Contribution to journalJournal articleResearchpeer-review

  1. CXCL13 predicts long term radiographic status in early rheumatoid arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Rheumatology: Biosimilars are here to stay

    Research output: Contribution to journalEditorialResearchpeer-review

  • Walter P Maksymowych
  • Mikkel Østergaard
  • Robert Landewé
  • William Barchuk
  • Ke Liu
  • Chantal Tasset
  • Leen Gilles
  • Thijs Hendrikx
  • Robin Besuyen
  • Xenofon Baraliakos
View graph of relations

OBJECTIVE: To assess the effect of filgotinib, which preferentially inhibits Janus kinase 1 (JAK1), on MRI measures of structural change in the SI joint in patients with active AS in the TORTUGA trial.

METHODS: Adults with active AS and inadequate response/intolerance to two or more NSAIDs were randomized 1:1 to filgotinib 200 mg (n = 58) or placebo (n = 58) once daily for 12 weeks. In this post hoc analysis, T1-weighted MRI scans of the SI joint were evaluated by two independent readers using Spondyloarthritis Research Consortium of Canada (SPARCC) Sacroiliac Joint Structural Score (SSS) definitions for erosion, backfill, fat metaplasia and ankylosis. Correlations between SPARCC SSS and improvement in clinical outcomes were also assessed.

RESULTS: MRI scans from 87 patients (48 filgotinib, 39 placebo) were evaluated. At baseline there were no notable differences between filgotinib and placebo for any MRI structural lesion types. From baseline to week 12, filgotinib was associated with a significant reduction in SI joint erosion score (P = 0.02) and an increase in backfill score (P = 0.005) vs placebo, with no significant between-group differences for ankylosis (P = 0.46) or fat metaplasia (P = 0.17). At week 12, the change in SPARCC MRI SI joint inflammation scores correlated positively with erosion scores but negatively with backfill scores.

CONCLUSION: The significant changes in MRI structural lesions induced by filgotinib in the SI joint by week 12 demonstrate that tissue repair can be observed very soon after starting treatment with a JAK1 preferential inhibitor. This could have prognostic implications for development of ankylosis.

TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT03117270.

Original languageEnglish
JournalRheumatology (Oxford, England)
Volume61
Issue number5
Pages (from-to)2063-2071
Number of pages9
ISSN1462-0324
DOIs
Publication statusPublished - 5 May 2022

Bibliographical note

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.

    Research areas

  • ankylosing spondylitis, filgotinib, inflammation, magnetic resonance imaging, sacroiliac joint, therapeutics, Pyridines, Spondylarthritis/drug therapy, Sacroiliac Joint/diagnostic imaging, Humans, Janus Kinase Inhibitors/therapeutic use, Magnetic Resonance Imaging/methods, Triazoles, Adult, Metaplasia/pathology, Spondylitis, Ankylosing/drug therapy

ID: 70405885